MCM
SAGE

Manchester Capital Management’s Sage Therapeutics SAGE Stock Holding History

Manchester Capital Management’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-550
Closed -$5.02K – 1339
2025
Q2 		$5.02K Hold
550
– – ﹤0.01% 903
2025
Q1 		$4.37K Hold
550
– – ﹤0.01% 918
2024
Q4 		$2.99K Hold
550
– – ﹤0.01% 954
2024
Q3 		$3.97K Hold
550
– – ﹤0.01% 923
2024
Q2 		$5.97K Buy
+550
New +$7.05K ﹤0.01% 831
2019
Q2 		– Sell
-362
Closed -$58K – 632
2019
Q1 		$58K Buy
+362
New +$52.4K 0.01% 377

Other funds holding SAGE

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Manchester Capital Management's SAGE Position: Q3 2025 in Review

Manchester Capital Management sold out of Sage Therapeutics (SAGE) in Q3 2025, closing a stake of 550 shares — an estimated $5.02K sold.

Manchester Capital Management first reported a position in SAGE in Q1 2019 and held it in 6 quarters. The position peaked at $58K in Q1 2019. 5 funds tracked by Wall St. Rank hold SAGE as of Q3 2025.

  • Manchester Capital Management reported no remaining Sage Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Manchester Capital Management sold 550 Sage Therapeutics shares in Q3 2025, an estimated $5.02K.
  • Manchester Capital Management first reported a position in Sage Therapeutics in Q1 2019 and held it in 6 quarters.
  • Manchester Capital Management's Sage Therapeutics position peaked at $58K in Q1 2019.
  • 5 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2025.

Based on Manchester Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.